Practical Preclinical Model for Assessing the Potential for Unconjugated Hyperbilirubinemia Produced by Human Immunodeficiency Virus Protease Inhibitors | Zendy

Dale J. Kempf | Zendy; Jeffrey F. Waring | Zendy; David C. Morfitt | Zendy; Paige Werner | Zendy; Brian Ebert | Zendy; Michael J. Mitten | Zendy; Bach Nguyen | Zendy; John T. Randolph | Zendy; David A. DeGoey | Zendy; Larry L. Klein | Zendy; Kennan C. Marsh | Zendy

Open Access

Practical Preclinical Model for Assessing the Potential for Unconjugated Hyperbilirubinemia Produced by Human Immunodeficiency Virus Protease Inhibitors

Author(s) -

Dale J. Kempf,

Jeffrey F. Waring,

David C. Morfitt,

Paige Werner,

Brian Ebert,

Michael J. Mitten,

Bach Nguyen,

John T. Randolph,

David A. DeGoey,

Larry L. Klein,

Kennan C. Marsh

Publication year - 2006

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.50.2.762-764.2006

Subject(s) - amprenavir , ritonavir , indinavir , atazanavir , protease , virology , protease inhibitor (pharmacology) , unconjugated hyperbilirubinemia , medicine , pharmacology , darunavir , human immunodeficiency virus (hiv) , biology , antiretroviral therapy , hiv 1 protease , enzyme , viral load , biochemistry , jaundice

A practical preclinical model for the hyperbilirubinemia produced by human immunodeficiency virus protease inhibitors has been developed. Indinavir and atazanavir produced significant hyperbilirubinemia, whereas amprenavir, the negative control, was indistinguishable from the ritonavir booster dose. This model was used to disqualify an exploratory protease inhibitor from development.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research